# US 11,998,481 B2 · Methods and compositions for iontophoretic drug delivery to the eye > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,998,481 B2 - Document ID: US11998481B2 - Status: Granted - Kind: B2 - Application number: 17/258,767 - Filed: 2019-08-02 - Published: 2021-04-29 - Granted: 2024-06-04 - Earliest claimed: 2018-08-02 - Assignees: University of Florida Research Foundation, Inc. - Applicants: University of Florida Research Foundation, Inc. - Inventors: Anuj Chauhan; Keith G. Christopher - Web page: https://patentgrep.com/patent/US11998481B2 ## CPC - A61F 9/0017: {implantable in, or in contact with, the eye, e.g. ocular inserts} - A61K 9/0048: {Eye, e.g. artificial tears} - A61N 1/0436: {Material of the electrode} - A61N 1/044: {Shape of the electrode} - A61N 1/303: {Constructional details (electrodes for external use A61N1/0428)} - G02C 7/04: Contact lenses for the eyes (disinfection or sterilisation of contact lenses A61L12/00) - A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B) - G02C: SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES (trial frames for testing the eyes A61B3/04; goggles or eyeshields not having the same features as spectacles A61F9/00) ## Abstract In one aspect, the disclosure relates to drug delivery devices for the ionophoretic delivery of a therapeutic agent(s) to the eye. In some aspects, the disclosed ionophoretic ocular delivery device is configured for delivery of a therapeutic agent to the anterior portion of the eye. In various aspects, the present disclosure provides methods for treatment of an ophthalmological disorder, disease, or clinical condition by delivering a therapeutic agent(s) to the eye using a disclosed ionophoretic ocular delivery device. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure. ## Claims ### Claim 1 An ionophoretic ocular delivery device comprising: a first electrode; a second electrode; a top lens component; an optional bottom lens component; one or more therapeutic agent; optionally one or more buffering agent; and a power source; wherein the first electrode is configured as one or more first spot electrode; and wherein the second electrode is configured as one or more second spot electrode. ### Claim 2 (depends on 1) The ionophoretic ocular delivery device of claim 1, wherein the first electrode is configured as an anode; and wherein the second electrode is configure as a cathode. ### Claim 3 (depends on 1) The ionophoretic ocular delivery device of claim 1, wherein the first electrode is configured as an outer concentric electrode; and wherein the second electrode is configured as an inner concentric electrode. ### Claim 4 (depends on 1) The ionophoretic ocular delivery device of claim 1, wherein the power source is an external power source. ### Claim 5 (depends on 1) The ionophoretic ocular delivery device of claim 1, wherein the power source is an integral power source. ### Claim 6 (depends on 4) The ionophoretic ocular delivery device of claim 4, wherein the integral power source is a water-activated battery. ### Claim 7 (depends on 1) The ionophoretic ocular delivery device of claim 1, wherein the power source is capable of providing a voltage of about 0.01 V to about 10 V; and wherein the power source is capable of providing a current of about 0.01 mAmp to about 50 mAmp. ### Claim 8 (depends on 1) The ionophoretic ocular delivery device of claim 1, wherein the top lens component comprises a polymer or a hydrogel. ### Claim 9 (depends on 8) The ionophoretic ocular delivery device of claim 8, wherein the polymer comprises a polymethyl methacrylate. ### Claim 10 (depends on 1) The ionophoretic ocular delivery device of claim 1, wherein the therapeutic agent is uniformly distributed within the top lens component. ### Claim 11 (depends on 1) The ionophoretic ocular delivery device of claim 1, wherein the therapeutic agent is an opthalmological drug. ### Claim 12 (depends on 11) The ionophoretic ocular delivery device of claim 11, wherein opthalmological drug is a glaucoma therapeutic agent, an ocular hypertension therapeutic agent, or a combination thereof. ### Claim 13 (depends on 1) The ionophoretic ocular delivery device of claim 1, wherein the one or more buffering agent is a Good's buffer. ### Claim 14 (depends on 13) The ionophoretic ocular delivery device of claim 13, wherein the Good's buffer is selected from the group consisting of BES, Bicine, HEPES, HEPPSO, POPSO, and Tricine. ### Claim 15 (depends on 1) The ionophoretic ocular delivery device of claim 1, wherein the first electrode comprises gold, a gold alloy, silver, a silver alloy, platinum, a platinum alloy, a conductive polymer, or mixtures thereof; and wherein the second electrode comprises gold, a gold alloy, silver, a silver alloy, platinum, a platinum alloy, a conductive polymer, or mixtures thereof. ### Claim 16 (depends on 15) The ionophoretic ocular delivery device of claim 15, wherein the first electrode and the second electrode comprise substantially identical materials. ### Claim 17 (depends on 1) A method of treating an ophthalmological disorder, disease, or clinical condition comprising administering one or more therapeutic agent using the ionophoretic ocular delivery device of claim 1, thereby treating the ophthalmological disorder, disease, or clinical condition. ### Claim 18 (depends on 17) The method of claim 17, wherein using the ionophoretic ocular delivery device comprises applying an electric field to the ionophoretic ocular delivery device for a period of from about 0.5 hours to about 2 hours. ### Claim 19 (depends on 17) The method of claim 17, wherein the ophthalmological disorder, disease, or clinical condition is selected from glaucoma, ocular hypertension, inflammation, keratitis, dry eye, uveitis, ophthalmological bacterial infection, ophthalmological fungal infection, macular edema, macular degeneration, herpetic conjunctivitis, blepharitis, retinal neovascularization, choroidal neovascularization, diabetic retinopathy, and combinations thereof.